Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
International Journal of Health Care Finance and Economics
|
November 6, 2012
Physician response to financial incentives when choosing drugs to treat breast cancer
Andrew J Epstein, Scott J Johnson
Health Care Management Science
|
June 15, 2005
Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/No-Go decisions
John A Vernon, W Keener Hughen, Scott J Johnson
Health Affairs (Project Hope)
|
September 9, 2011
Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings
Laurence C Baker, Scott J Johnson, Dendy Macaulay, et al.
Pharmacoeconomics
|
April 12, 2006
Economic and developmental considerations for pharmacogenomic technology
John A Vernon, Scott J Johnson, W Keener Hughen, et al.
Journal of Health Politics, Policy and Law
|
May 6, 2011
Commercial importation of prescription drugs in the United States: short-run implications
Patricia M Danzon, Scott J Johnson, Genia Long, et al.
Journal of Medical Economics
|
August 15, 2017
The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States
Daniel Bin Ng, Robert Espinosa, Scott J Johnson, et al.
Journal of Medical Economics
|
March 11, 2024
The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States
Lasair O'Callaghan, Elizabeth Chertavian, Scott J Johnson, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
April 3, 2019
Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression
Si-Tien Wang, Ian M Anderson, Dominic Mitchell, et al.
Journal of Medical Economics
|
May 13, 2016
Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection
Scott J Johnson, Hélène Parisé, Suchin Virabhak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 14, 2013
An economic model of Parkinson's disease: implications for slowing progression in the United States
Scott J Johnson, Melissa D Diener, Anna Kaltenboeck, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
International Journal of Health Care Finance and Economics
|
November 6, 2012
Physician response to financial incentives when choosing drugs to treat breast cancer
Andrew J Epstein, Scott J Johnson
Health Care Management Science
|
June 15, 2005
Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/No-Go decisions
John A Vernon, W Keener Hughen, Scott J Johnson
Health Affairs (Project Hope)
|
September 9, 2011
Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings
Laurence C Baker, Scott J Johnson, Dendy Macaulay, et al.
Pharmacoeconomics
|
April 12, 2006
Economic and developmental considerations for pharmacogenomic technology
John A Vernon, Scott J Johnson, W Keener Hughen, et al.
Journal of Health Politics, Policy and Law
|
May 6, 2011
Commercial importation of prescription drugs in the United States: short-run implications
Patricia M Danzon, Scott J Johnson, Genia Long, et al.
Journal of Medical Economics
|
August 15, 2017
The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States
Daniel Bin Ng, Robert Espinosa, Scott J Johnson, et al.
Journal of Medical Economics
|
March 11, 2024
The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States
Lasair O'Callaghan, Elizabeth Chertavian, Scott J Johnson, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
April 3, 2019
Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression
Si-Tien Wang, Ian M Anderson, Dominic Mitchell, et al.
Journal of Medical Economics
|
May 13, 2016
Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection
Scott J Johnson, Hélène Parisé, Suchin Virabhak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 14, 2013
An economic model of Parkinson's disease: implications for slowing progression in the United States
Scott J Johnson, Melissa D Diener, Anna Kaltenboeck, et al.
Page
of 3